Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB, Irish JM, Wälchli S, Myklebust JH(2022) Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression J Immunol, 209(10), 2042-2053 DOI 10.4049/jimmunol.2200144, PubMed 36426942
Isaksen KT, Beiske K, Smeland EB, Jørgensen J, Brodtkorb M, Myklebust JH, Jerkeman M, Meriranta L, Karjalainen-Lindsberg ML, Leppä S, Scott DW, Holte H, Blaker YN(2020) The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma EJHaem, 2(1), 104-108 DOI 10.1002/jha2.109, PubMed 35846101
Group leader: June H. Myklebust, Email: junehm@rr-research.no, Phone: +47 22781413 Postal address: Department of Cancer Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway
